8 unchanged sentences
The following performance graph is being furnished as part of this annual report and shall not be deemed "filed" with the SEC or incorporated by reference into any of our filings under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.
−Removed: The following graph shows the total shareholder return of an investment of $100 in cash at market close on October 2, 2015 (the first day of trading of our ordinary shares) through December 31, 2019 for (1) our ordinary shares, (2) the Russell 2000 Index, and (3) the Nasdaq Biotechnology Index.
+Added: The graph below matches our cumulative 5-Year total shareholder return on our ordinary shares with the cumulative total returns of the Russell 2000 index and the Nasdaq Biotechnology index.
+Added: The graph tracks the performance of a $100 investment in our ordinary shares and in each index (with the reinvestment of all dividends) from December 31, 2015 to December 31, 2020.
Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends;
5 unchanged sentences
NASDAQ Biotechnology 100.00 78.65 95.67 87.19 109.08 137.90
−Removed: Table of Conten ts
Recent Sales of Unregistered Securities
4 unchanged sentences
Exercise of Warrants January 1, 2018 to December 31, 2018 440,960 $ 10
−Removed: Exercise of Warrants January 1, 2018 to December 31, 2018 440,960 $ 10
Issuer Purchases of Equity Securities
19 unchanged sentences
Total 13,686,477 $ 17.66 20,338,061
−Removed: Table of Conten ts
SELECTED FINANCIAL DATA
−Removed: The following tables set forth our consolidated statements of operations data:
−Removed: Year ended December 31,
−Removed: dollars in thousands 2019 2018 2017 2016 2015
−Removed: Net revenues $ 351,318 $ 248,069 $ 177,026 $ 82,888 $ 33,087
−Removed: Cost of revenues 88,606 80,048 55,609 39,870 20,610
−Removed: Impairment of field equipment — — — 6,412 —
−Removed: Gross Profit 262,712 168,021 121,417 36,606 12,477
−Removed: Research, development and clinical trials 79,003 50,574 38,103 41,467 43,748
−Removed: Sales and marketing 96,675 77,663 63,528 59,449 38,861
−Removed: General and administrative 87,948 73,456 59,114 51,007 33,864
−Removed: Total Operating expenses 263,626 201,693 160,745 151,923 116,473
−Removed: Operating income (loss) (914) (33,672) (39,328) (115,317) (103,996)
−Removed: Financial expenses (income), net 7,910 12,270 9,169 6,147 3,151
−Removed: Income (loss) before income tax (8,824) (45,942) (48,497) (121,464) (107,147)
−Removed: Income tax (1,594) 17,617 13,165 10,381 4,434
−Removed: Net income (loss) $ (7,230) $ (63,559) $ (61,662) $ (131,845) $ (111,581)
−Removed: Basic and diluted net income (loss) per ordinary share $ (0.07) $ (0.69) $ (0.70) $ (1.54) $ (3.67)
−Removed: Non-cash share-based compensation expense included in costs and expenses:
−Removed: Year ended December 31,
−Removed: dollars in thousands 2019 2018 2017 2016 2015
−Removed: Cost of revenues $ 2,231 $ 1,261 $ 467 $ 623 $ 174
−Removed: Research, development and clinical trials 7,570 4,709 3,587 3,155 2,529
−Removed: Sales and marketing 11,897 7,393 3,784 5,111 2,496
−Removed: General and administrative 30,718 26,483 19,278 12,552 6,661
−Removed: Total share-based compensation expense $ 52,416 $ 39,846 $ 27,116 $ 21,441 $ 11,860
−Removed: Consolidated balance sheet data:
−Removed: dollars in thousands 2019 2018 2017 2016 2015
−Removed: Cash and cash equivalents $ 177,321 $ 140,622 $ 78,592 $ 99,780 $ 119,423
−Removed: Short-term investments 148,769 105,256 104,719 119,854 150,001
−Removed: Total assets 479,448 339,793 265,298 282,081 307,336
−Removed: Working capital 353,636 256,809 194,932 224,991 265,277
−Removed: Current liabilities 86,311 64,560 50,202 36,882 28,627
−Removed: Long - term liabilities 175,347 162,974 101,532 102,854 27,889
−Removed: Total shareholders' equity $ 217,790 $ 112,259 $ 113,564 $ 142,345 $ 250,820
−Removed: Table of Conten ts
−Removed: Condensed cash flow data:
−Removed: Year ended December 31,
−Removed: dollars in thousands 2019 2018 2017 2016 2015
−Removed: Net cash provided by (used in) operating activities $ 26,620 $ (1,865) $ (33,134) $ (107,592) $ (99,884)
−Removed: Net cash provided by (used in) investing activities (51,667) (5,493) 8,628 12,996 (115,269)
−Removed: Net cash provided by (used in) financing activities 61,681 69,369 5,168 75,124 276,989
−Removed: Effect of exchange rate differences on cash and cash equivalents 26 27 8 10 —
−Removed: Net increase (decrease) in cash, cash equivalents and restricted cash $ 36,660 $ 62,038 $ (19,330) $ (19,462) $ 61,836
+Added: Omitted pursuant to SEC Release 33-10890, which eliminated Item 301 of Regulation S-K.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.